JP2023538085A5 - - Google Patents

Info

Publication number
JP2023538085A5
JP2023538085A5 JP2023511995A JP2023511995A JP2023538085A5 JP 2023538085 A5 JP2023538085 A5 JP 2023538085A5 JP 2023511995 A JP2023511995 A JP 2023511995A JP 2023511995 A JP2023511995 A JP 2023511995A JP 2023538085 A5 JP2023538085 A5 JP 2023538085A5
Authority
JP
Japan
Prior art keywords
polypeptide
acid sequence
coronavirus
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023511995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538085A (ja
Filing date
Publication date
Priority claimed from US16/996,740 external-priority patent/US11149286B1/en
Application filed filed Critical
Publication of JP2023538085A publication Critical patent/JP2023538085A/ja
Publication of JP2023538085A5 publication Critical patent/JP2023538085A5/ja
Priority to JP2025135332A priority Critical patent/JP2025183225A/ja
Pending legal-status Critical Current

Links

JP2023511995A 2020-08-17 2021-08-17 アデノウイルスベクター及びアデノウイルスベクターの使用方法 Pending JP2023538085A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135332A JP2025183225A (ja) 2020-08-17 2025-08-15 アデノウイルスベクター及びアデノウイルスベクターの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063066740P 2020-08-17 2020-08-17
US63/066,740 2020-08-17
US16/996,740 US11149286B1 (en) 2020-08-17 2020-08-18 Adenovirus vectors and methods for using adenovirus vectors
US16/996,740 2020-08-18
PCT/US2021/046333 WO2022040204A1 (en) 2020-08-17 2021-08-17 Adenovirus vectors and methods for using adenovirus vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135332A Division JP2025183225A (ja) 2020-08-17 2025-08-15 アデノウイルスベクター及びアデノウイルスベクターの使用方法

Publications (2)

Publication Number Publication Date
JP2023538085A JP2023538085A (ja) 2023-09-06
JP2023538085A5 true JP2023538085A5 (https=) 2024-08-13

Family

ID=78083221

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023511995A Pending JP2023538085A (ja) 2020-08-17 2021-08-17 アデノウイルスベクター及びアデノウイルスベクターの使用方法
JP2025135332A Pending JP2025183225A (ja) 2020-08-17 2025-08-15 アデノウイルスベクター及びアデノウイルスベクターの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135332A Pending JP2025183225A (ja) 2020-08-17 2025-08-15 アデノウイルスベクター及びアデノウイルスベクターの使用方法

Country Status (11)

Country Link
US (4) US11149286B1 (https=)
EP (1) EP4196092A4 (https=)
JP (2) JP2023538085A (https=)
KR (1) KR20230079359A (https=)
CN (1) CN116887820A (https=)
AU (1) AU2021329309A1 (https=)
BR (1) BR112023002932A2 (https=)
CA (1) CA3189832A1 (https=)
MX (1) MX2023002008A (https=)
WO (1) WO2022040204A1 (https=)
ZA (1) ZA202303601B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US11149286B1 (en) * 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
WO2022216895A1 (en) * 2021-04-09 2022-10-13 University Of Florida Research Foundation, Incorporated Methods, kits, and approaches for viral vaccines
AU2023347247A1 (en) * 2022-09-19 2025-04-10 Mayo Foundation For Medical Education And Research Methods and materials for using adenovirus vectors to immunize mammals
WO2025129186A1 (en) * 2023-12-14 2025-06-19 The Trustees Of The University Of Pennsylvania Clostridioides difficile vaccine and methods of use
WO2025196724A1 (en) * 2024-03-21 2025-09-25 Moat Biotechnology Corporation Methods for inducing immune responses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
US20060062764A1 (en) 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
EA017887B1 (ru) * 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
EP3466443B1 (en) * 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
EP4079750A3 (en) * 2018-11-21 2023-01-04 Mayo Foundation for Medical Education and Research Adenoviruses and methods for using adenoviruses
CN111358943A (zh) * 2020-03-03 2020-07-03 重庆医科大学附属永川医院 一种新冠病毒的双靶向免疫增强型多价疫苗及其制备方法
CN111218459B (zh) * 2020-03-18 2020-09-11 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
GB202004974D0 (en) * 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
CN111529685A (zh) * 2020-04-21 2020-08-14 厦门诺康得生物科技有限公司 抗呼吸道病毒感染的鼻腔喷雾制剂
RU2720614C9 (ru) * 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN111560076B (zh) * 2020-05-15 2021-05-07 广州百暨基因科技有限公司 一种嵌合抗原受体免疫细胞及其制备方法和应用
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors

Similar Documents

Publication Publication Date Title
JP2023538085A5 (https=)
JP6983665B2 (ja) アデノウイルスポリヌクレオチド及びポリペプチド
CN106999565B (zh) 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗
Gherardi et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner
CN109803677A (zh) 用于α病毒疫苗接种的组合物和方法
JPH06508039A (ja) 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス
JP2023062157A (ja) サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
US20260098063A1 (en) Human papillomavirus vaccines and uses of the same
US20240093161A1 (en) Simian adenoviral vectors with two expression cassettes
JP2024535145A5 (https=)
JP4615311B2 (ja) ウイルスベクターおよびその遺伝子治療のための使用
KR20230113331A (ko) 인간 파필로마 바이러스 백신 및 hpv 연관된 질환에 대한 이의 용도
EP0630257B1 (en) Thymus-derived, immune-enhancing agent for therapeutic use in immunocompromised hosts
JP2003230396A (ja) ｇｐ３５０／２２０非スプライシング変異体
FI117054B (fi) Interleukiini-15:n valmistusmenetelmä ja sitä koodaava DNA-sekvenssi
EP4175971A1 (en) Stabilized corona virus spike protein fusion proteins
WO2022077591A1 (zh) 一种重组腺病毒在制备预防病毒的药物中的用途
JP5884100B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス
WO2006022215A1 (ja) SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
CN1094974C (zh) 表达人白细胞介素12的重组腺病毒及其制法和用途
CN115975053A (zh) 靶向新型冠状病毒的疫苗
US20220364115A1 (en) Enhanced promoter
Lindley et al. Construction and characterization of adenovirus co-expressing hepatitis B virus surface antigen and interleukin-6
WO1992003574A1 (en) Cytokine production
Zurkova et al. Attenuation of vaccinia virus by the expression of human Flt3 ligand